Anticoagulants Global Market Report 2024

Anticoagulants, commonly known as blood thinners, are drugs used to prevent and treat blood clots in the heart and blood arteries. They work by slowing down the body's clotting process, reducing the risk of clot formation.

The main drug classes of anticoagulants include Factor Xa Inhibitor, Heparin & LMWH (Low Molecular Weight Heparin), Vitamin K Antagonist, and others. Factor Xa inhibitors specifically and reversibly block the function of clotting factor Xa, preventing clot formation. Anticoagulants can be administered orally or through injections, and they are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies. Anticoagulants are used in the treatment of conditions such as venous thromboembolism, atrial fibrillation or flutter, coronary artery disease, among others. They are employed in various healthcare settings, including hospitals, home care, specialty centers, and others.

The anticoagulants market research report is one of a series of new reports that provides anticoagulants market statistics, including anticoagulants industry global market size, regional shares, competitors with an anticoagulants market share, detailed anticoagulants market segments, market trends and opportunities, and any further data you may need to thrive in the anticoagulants industry. This anticoagulants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anticoagulants market size has grown rapidly in recent years. It will grow from $45.18 billion in 2023 to $49.89 billion in 2024 at a compound annual growth rate (CAGR) of 10.4%. The observed growth in the historical period can be attributed to several factors, including an aging population, increased prevalence of cardiovascular diseases, rising awareness about the importance of anticoagulant therapy, the expansion of indications for anticoagulant use, and an increased incidence of venous thromboembolism (VTE) and atrial fibrillation. These factors collectively contributed to the growing demand for anticoagulants and their expanded use in various medical conditions.

The anticoagulants market size is expected to see rapid growth in the next few years. It will grow to $77.71 billion in 2028 at a compound annual growth rate (CAGR) of 11.7%. The anticipated growth in the forecast period can be attributed to several factors, including the expansion of indications for novel anticoagulant drugs, rising healthcare expenditure, the emergence of novel oral anticoagulants (NOACs) as primary treatment options, financial support offered by central authorities to revamp healthcare facilities, and the expansion of healthcare infrastructure. Major trends expected in the forecast period include advancements in medical technologies and diagnostic methods, the integration of artificial intelligence and data analytics in anticoagulant therapy, a growing emphasis on patient education and adherence programs, and the development of reversal agents.

The escalating prevalence of cardiovascular diseases (CVDs) stands as a primary driver propelling the growth of the anticoagulants market in the foreseeable future. CVDs encompass a spectrum of heart and blood vessel issues and remain a leading cause of global mortality, particularly prevalent in low- and middle-income nations, accounting for a significant portion of CVD-related deaths worldwide. Direct oral anticoagulants, a form of anticoagulation pharmacotherapy, are instrumental in reducing thrombosis in various cardiovascular scenarios. As per the World Health Organization's 2021 report, cardiovascular diseases claimed the lives of 17.9 million individuals globally, representing 32% of all deaths, with 85% attributed to heart attacks and strokes. Consequently, the rise in cardiovascular diseases serves as a pivotal driver for the expansion of the anticoagulants market.

The surge in the number of hospitals is anticipated to drive the growth of the anticoagulants market moving forward. Hospitals serve as crucial healthcare facilities offering medical treatment, care, and support to individuals grappling with diverse illnesses, injuries, or medical conditions. Anticoagulants find extensive use in hospitals for preventing blood clots, managing thromboembolic disorders, addressing heart conditions, reducing recurrent strokes, and mitigating postoperative complications. For instance, data from Interweave Textiles Limited in August 2023 indicates there are 1148 hospitals in the UK, illustrating a growing healthcare infrastructure. This surge in hospital numbers contributes significantly to the expansion of the anticoagulants market.

The ongoing clinical trials investigating anticoagulant treatments for COVID-19 are shaping the trajectory of the anticoagulants market. Major companies within the anticoagulants sector are intensely focused on conducting clinical trials for anticoagulant medications to mitigate the risk of COVID-19-related blood clotting in adults. For instance, in March 2021, the National Institutes of Health (NIH) in the USA initiated the final phase of three Phase III clinical trials for blood thinners (anticoagulants) to prevent life-threatening blood clots in elderly individuals with COVID-19. These ACTIV-4 trials aim to address concerns and establish the efficacy of anticoagulants, also known as antithrombotics, in the treatment of COVID-19.

Prominent entities within the anticoagulants market are directing their focus towards innovative products, such as the sodium citrate 4% anticoagulant solution, to bolster their market revenues. This medical solution consists of a liquid form containing 4% sodium citrate, serving the purpose of preventing blood clotting. For instance, in August 2023, Fresenius Kabi AG, a Germany-based healthcare group specializing in pharmaceuticals and medical devices, introduced the sodium citrate 4% anticoagulant solution. When utilized in conjunction with apheresis equipment, this solution becomes vital for collecting and preserving blood and its components. The 250 mL container of sodium citrate 4% anticoagulant solution is meticulously crafted to adhere to Canada's stringent requirements for plasma donation. By binding calcium ions, sodium citrate effectively prevents the coagulation cascade, maintaining blood in a liquid state suitable for diagnostic testing and various medical procedures.

In August 2022, Pharmaniaga Berhad, a Malaysia-based pharmaceutical company, forged a partnership with Suzhou Ronnsi Pharma Co. Ltd. This strategic collaboration aims to address the escalating demand for therapies targeting non-communicable diseases, driven by an aging population, and specifically caters to the burgeoning market for halal medications. The partnership between Pharmaniaga Berhad and Suzhou Ronnsi Pharma Co. Ltd aims to facilitate commerce in pharmaceutical products, research and development initiatives, and ultimately, the production of a halal ovine anticoagulant product. Suzhou Ronnsi Pharma Co. Ltd, based in China, specializes in manufacturing anticoagulants and forms a crucial part of this collaboration aimed at meeting the growing demand for halal pharmaceuticals in the market.

Major companies operating in the in the anticoagulants market report are GlaxoSmithKline plc, Leo Pharma A/S, Alexion Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc., Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Mylan N. V., Otsuka Holdings Co. Ltd., Pfizer Inc., Sanofi S. A., Apotex Inc., Aspen Pharmacare Holdings Limited, AstraZeneca plc, Bristol-Myers Squibb Company, CSL Behring, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Fresenius Kabi AG, Hikma Pharmaceuticals plc, Johnson & Johnson, Lupin Limited, Mitsubishi Tanabe Pharma Corporation, Natco Pharma Limited, Novartis International AG, Portola Pharmaceuticals Inc., Strides Pharma Science Limited, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Torrent Pharmaceuticals Limited, Zydus Cadila Healthcare Limited

North America was the largest region in the anticoagulants market in 2023. The regions covered in the anticoagulants market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the anticoagulants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The anticoagulants market consists of sales of rivaroxaban, dabigatran, apixaban, and edoxaban. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified)).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.